ARGENX SE is 7.8x more valuable than Kymera Therapeutics, Inc. by market capitalization ($55.29 B vs $7.09 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | ARGX |
|---|---|---|
| Market cap | $7.09 B | $55.29 B |
| US-listed rank | #1167 | #303 |
| Revenue (latest FY) | $39.21M | - |
| Net income (latest FY) | $311.35M | - |
| Net margin | 794.0% | - |
| P/E (trailing FY) | 22.8 | - |
| SEC filings | 575 | 272 |
ARGENX SE is 7.8x more valuable than Kymera Therapeutics, Inc. by market capitalization ($55.29 B vs $7.09 B).
Full pages: Kymera Therapeutics, Inc. and ARGENX SE, or browse the full rankings.